AstraZeneca to Build China-Dedicated Supply Chain to Support $80B Revenue Target by 2030

According to the Financial Times, Pascal Soriot, CEO of AstraZeneca, said on May 21 that sales and innovation in China would help the company reach its new revenue target of $80 billion by 2030. Soriot said that AstraZeneca has established a manufacturing plant in Qingdao that will serve only China and other emerging markets, and he noted that the company "is working to build a China-focused supply chain." (Jiemian)Original Link